Related Articles
The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells
Hereditary breast and ovarian cancer susceptibility genes (Review)
Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer (Review)
Triple‑negative breast cancer therapy: Current and future perspectives (Review)
Identification of long non‑coding RNA‑mediated transcriptional dysregulation triplets reveals global patterns and prognostic biomarkers for ER+/PR+, HER2‑ and triple negative breast cancer